Mintorlan (Tamsulosin Hydrochloride, Solifenacin Succinate)

Tamsulosin Hydrochloride / Solifenacin Succinate, the active ingredient in Mintorlan, is an alpha‑1 adrenergic antagonist / muscarinic (M3) antagonist presented as an oral tablet for oral use. It treats benign prostatic hyperplasia and overactive bladder in adult patients, improving urinary flow and reducing bladder overactivity.

GNH USA supplies Mintorlan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mintorlan combines tamsulosin and solifenacin to address lower urinary tract disorders.

Benign prostatic hyperplasia (BPH): improves urine flow and reduces urinary retention. Overactive bladder (OAB): decreases urgency episodes and increases bladder capacity. Urinary urgency: alleviates frequent urges to void, helping patients regain control.

Common Side Effects: - Dizziness or light‑headedness - Dry mouth - Constipation - Headache - Blurred vision - Nausea

Serious or Rare Side Effects: - Priapism or prolonged erection - Severe hypotension leading to fainting - Acute urinary retention - Allergic reactions such as rash or swelling - QT interval prolongation or cardiac arrhythmia

Before initiating Mintorlan, consider the following precautions. - Blood pressure monitoring: watch for orthostatic hypotension, especially at treatment start. - Renal function assessment: adjust use in patients with severe renal impairment. - Hepatic impairment: evaluate liver function, as metabolism may be affected. - Concomitant anticholinergic load: avoid excessive anticholinergic burden. - Urinary retention risk: monitor patients with existing retention symptoms. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mintorlan may interact with several drug classes.

Major Interactions (Avoid): - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Other alpha‑1 blockers (e.g., prazosin, doxazosin): additive hypotensive effect. - Additional antimuscarinic agents (e.g., oxybutynin): heightened anticholinergic side effects.

Moderate Interactions (Monitor Closely):\n- Diuretics: may exacerbate orthostatic hypotension. - Antihypertensives: additive blood pressure lowering. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy of tamsulosin.